An Expert Report on Parecoxib (DB08439): Pharmacology, Clinical Efficacy, and Regulatory Context

Executive Summary

Parecoxib is a parenterally administered, selective cyclooxygenase-2 (COX-2) inhibitor, classified as a non-steroidal anti-inflammatory drug (NSAID). It functions as a water-soluble prodrug, which is rapidly and completely hydrolyzed in vivo to its pharmacologically active metabolite, valdecoxib.[1] Developed to provide potent analgesia in the perioperative setting where oral administration is not feasible, parecoxib is the first and only injectable coxib available for clinical use.[1] Its primary indication is the short-term management of postoperative pain in adults.[4]

The clinical profile of parecoxib is defined by a rapid onset of analgesia, typically within 7-13 minutes, and a sustained effect that supports a 6- to 12-hour dosing interval, making it a valuable component of multimodal analgesic strategies.[1] Its mechanism of action, through the selective inhibition of the COX-2 enzyme by valdecoxib, effectively reduces the synthesis of pro-inflammatory prostaglandins, thereby alleviating pain and inflammation.[2] This selectivity confers a significant safety advantage over traditional, non-selective NSAIDs by sparing the COX-1 enzyme, which is crucial for maintaining gastric mucosal integrity and platelet function. Consequently, parecoxib is associated with a lower risk of gastrointestinal ulceration and does not interfere with platelet aggregation, a critical consideration in the surgical setting.[8]

However, as a member of the coxib class, parecoxib is associated with potential cardiovascular and dermatological risks. An increased risk of thromboembolic events, particularly following coronary artery bypass graft (CABG) surgery, has led to a contraindication for its use in this context.[11] Furthermore, rare but serious skin reactions, including Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN), have been linked to valdecoxib, necessitating vigilance, particularly in patients with a history of sulfonamide allergy.[1]

The regulatory history of parecoxib is notably divergent. It has been approved and widely used in the European Union (under the brand name Dynastat) and numerous other countries since 2002, where its benefits for postoperative pain are considered to outweigh its risks in appropriate patient populations.[1] In contrast, the United States Food and Drug Administration (FDA) did not approve parecoxib in 2005.[12] This decision, made in the highly cautious regulatory climate following the withdrawal of rofecoxib (Vioxx), is thought to have been influenced by both the documented cardiovascular risks in CABG patients and significant political pressure, rather than a uniquely unfavorable risk profile for its intended short-term use.[1] This report provides an exhaustive analysis of parecoxib's chemical properties, pharmacology, pharmacokinetics, clinical efficacy, safety profile, and the complex global regulatory landscape that has shaped its clinical availability.

Drug Identification and Physicochemical Properties

A precise understanding of a drug's identity and its fundamental physical and chemical characteristics is essential for its safe and effective use. This section details the nomenclature, structural properties, and formulation characteristics of parecoxib.

Nomenclature, Synonyms, and Database Identifiers

Parecoxib is identified by a variety of names and codes across chemical, pharmacological, and regulatory databases. The drug is most commonly available as its sodium salt to enhance solubility for injection. Key identifiers are consolidated in Table 1 below.

• Generic Name: Parecoxib [13]
• Brand Name: Dynastat [1]
• Drug Class: Non-steroidal anti-inflammatory drug (NSAID); Selective COX-2 inhibitor (Coxib) [4]
• Chemical Synonyms: SC-69124, Vorth-P, Valus-P, Parocoxib [14]
• ATC Code: M01AH04 [1]

Chemical Structure and Properties

Parecoxib is an N-acylsulfonamide, a synthetic organic compound featuring an isoxazole ring structure.[15] Its chemical formula as a free base is

C19​H18​N2​O4​S, with a corresponding molar mass of 370.42 g·mol⁻¹.[1] The clinically used form, parecoxib sodium, has the formula

C19​H17​N2​NaO4​S and a molar mass of approximately 392.41 g·mol⁻¹.[11] The structure of parecoxib has been unequivocally confirmed through advanced analytical techniques, including single crystal X-ray analysis, nuclear magnetic resonance (NMR), infrared (IR) spectroscopy, and mass spectrometry (MS).[3] The molecule contains no asymmetric centers, meaning it is not chiral.[3] A critical feature of its structure is the sulfonamide moiety, which is implicated in both its selective binding to the COX-2 enzyme and its potential for hypersensitivity reactions in susceptible individuals.[7]

Formulation, Solubility, and Stability

The development of parecoxib was a direct and deliberate pharmaceutical strategy to overcome a significant formulation challenge. Its active metabolite, valdecoxib, is a potent COX-2 inhibitor but is poorly soluble in water, rendering it unsuitable for parenteral administration.[3] By modifying valdecoxib into its N-acylsulfonamide prodrug, parecoxib, and formulating it as a sodium salt, a highly water-soluble compound was created, enabling its use as an injectable medication.[1] This highlights a sophisticated interplay between medicinal chemistry and pharmaceutical science to unlock a drug's therapeutic potential for a specific clinical niche—the perioperative setting.

Parecoxib sodium is a white to off-white crystalline solid, typically supplied as a lyophilized (freeze-dried) powder for reconstitution.[11] Its aqueous solubility is markedly pH-dependent; at 20°C, solubility is 18 mg/mL at a pH of 7.8 but increases over twelve-fold to 220 mg/mL at a pH of 8.3.[3] The commercial formulation includes dibasic sodium phosphate as a buffering agent to maintain the pH of the reconstituted solution within the optimal range of 7.5 to 8.5, ensuring complete dissolution.[3] The drug substance is stable for at least two years under standard storage conditions, and reconstituted solutions with compatible diluents (e.g., 0.9% sodium chloride, 5% glucose) are chemically and physically stable for up to 48 hours.[3]

Property	Value	Source(s)
DrugBank ID	DB08439	1
CAS Number	198470-84-7 (Parecoxib) 198470-85-8 (Parecoxib sodium)	1
IUPAC Name	N-{[4-(5-methyl-3-phenylisoxazol-4-yl)phenyl] sulfonyl}propanamide	1
Molecular Formula	C19​H18​N2​O4​S (Parecoxib) C19​H17​N2​NaO4​S (Parecoxib sodium)	1
Molar Mass	370.42 g·mol⁻¹ (Parecoxib) 392.41 g·mol⁻¹ (Parecoxib sodium)	1
Appearance	White to off-white crystalline solid/powder	11
Solubility (Sodium Salt)	Water-soluble; 18 mg/mL at pH 7.8, 220 mg/mL at pH 8.3	3
pKa (Strongest Acidic)	6.7	21
Melting Point	148.9-157°C (Parecoxib) 273-275°C (Parecoxib sodium)	16
Table 1: Key Identifiers and Physicochemical Properties of Parecoxib

Pharmacology and Mechanism of Action

Parecoxib exerts its therapeutic effects through a well-defined primary mechanism involving the selective inhibition of the COX-2 enzyme, complemented by recently discovered secondary actions on neuronal ion channels.

Classification: A Parenteral Prodrug and Selective COX-2 Inhibitor

Parecoxib holds a unique position in clinical pharmacology. It is classified as a non-steroidal anti-inflammatory drug (NSAID) and is a member of the coxib subclass, characterized by selective inhibition of the COX-2 enzyme.[4] Critically, parecoxib is an inactive prodrug.[14] Following parenteral administration, it is rapidly and completely hydrolyzed in the liver to its pharmacologically active form, valdecoxib, which is responsible for all of its COX-2-mediated effects.[1]

The Cyclooxygenase Pathway: Differentiating COX-1 and COX-2 Functions

To comprehend parecoxib's action, it is essential to understand the roles of the two primary cyclooxygenase isoforms. Both COX-1 and COX-2 enzymes catalyze the conversion of arachidonic acid into prostaglandins, which are key lipid mediators in the body.[2] However, their expression patterns and functions are distinct:

• Cyclooxygenase-1 (COX-1): This isoform is constitutively expressed in most tissues and is considered a "housekeeping" enzyme. It synthesizes prostaglandins that are vital for physiological homeostasis, including the protection of the gastric mucosa from acid damage, maintenance of renal blood flow, and regulation of platelet aggregation.[2] The inhibition of COX-1 by traditional, non-selective NSAIDs (e.g., ibuprofen, ketorolac) is responsible for their most common and serious side effects, namely gastrointestinal ulceration and bleeding.[24]
• Cyclooxygenase-2 (COX-2): This isoform is typically expressed at low levels in most tissues but is rapidly and dramatically upregulated at sites of injury and inflammation by stimuli such as cytokines and growth factors.[2] The prostaglandins produced by COX-2 are the principal mediators of the cardinal signs of inflammation: pain, swelling, redness, and heat.[7] The central hypothesis behind the development of coxibs was that selectively inhibiting COX-2 would provide potent anti-inflammatory and analgesic effects while sparing the protective functions of COX-1, thereby improving gastrointestinal safety.[10]

Molecular Basis of Selective Inhibition by Valdecoxib

The selectivity of valdecoxib for COX-2 is rooted in a subtle but critical structural difference between the active sites of the two enzyme isoforms. The active site of COX-2 is approximately 20-25% larger than that of COX-1 and contains a distinct hydrophilic side-pocket.[7] This difference is primarily due to the substitution of a bulky isoleucine residue at position 523 in COX-1 with a smaller valine residue in COX-2.[7]

This structural variation allows the bulky sulfonamide side group of valdecoxib to fit snugly into the side-pocket of the COX-2 active site, forming strong binding interactions.[7] Conversely, this same bulky group is sterically hindered from entering the narrower, more constricted active site of the COX-1 enzyme.[7] This "lock-and-key" difference forms the molecular basis of its selectivity.

Pharmacodynamic studies confirm this structural advantage. Valdecoxib is an extremely potent inhibitor of recombinant human COX-2, with a half-maximal inhibitory concentration (IC50​) of 0.005 µM. In contrast, its IC50​ for COX-1 is 150 µM, demonstrating a selectivity ratio of approximately 30,000-fold in this assay.[29] The binding to COX-2 is characterized by a high affinity (2.6 nM), a rapid rate of inactivation, and a slow dissociation rate, with a half-life of the enzyme-inhibitor complex of about 98 minutes, leading to a sustained, time-dependent inhibition.[7]

Non-COX-Mediated Effects on Neuronal Ion Channels

While the primary mechanism of action is well-established, emerging evidence suggests a more complex pharmacological profile. A 2018 study in European Journal of Pharmacology revealed that parecoxib can directly inhibit several types of neuronal ion channels that are critical for nerve impulse generation and propagation.[30] Specifically, parecoxib was shown to reversibly reduce the amplitude of delayed-rectifier potassium currents (

IK(DR)​), M-type potassium currents, and voltage-gated sodium currents in neuronal cells.[30]

This action is entirely independent of its effects on the COX pathway; the study authors explicitly state that the effects "are direct and unrelated to its inhibition of the enzymatic activity of cyclooxygenase-2".[30] This discovery suggests a potential dual mechanism of analgesia. The conventional understanding is that coxibs reduce pain by decreasing the production of inflammatory prostaglandins, which in turn reduces the sensitization of peripheral and central pain pathways. The direct inhibition of neuronal ion channels represents a parallel mechanism that could contribute to its overall analgesic effect by directly dampening neuronal excitability and signal transmission. This secondary action may help explain the rapid onset of analgesia and the robust efficacy observed in clinical settings, suggesting a more nuanced neuropharmacological profile than previously appreciated for this class of drugs.

Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

The pharmacokinetic profile of parecoxib is characterized by its rapid conversion from an inactive prodrug to a long-acting active metabolite. This two-stage process is fundamental to its clinical utility, enabling rapid onset and sustained duration of action from a single parenteral dose.

Absorption and Bioavailability Following Parenteral Administration

As parecoxib is administered exclusively by intravenous (IV) or intramuscular (IM) injection, it bypasses first-pass metabolism and has a bioavailability of 100%.[1] Following administration, the conversion to the active metabolite, valdecoxib, is swift. Peak plasma concentrations (

Cmax​) of valdecoxib are achieved rapidly, occurring in approximately 30 minutes following an IV bolus dose and in about 1 hour after an IM injection.[31]

Distribution, Volume of Distribution, and Plasma Protein Binding

Once formed, valdecoxib is widely distributed throughout the body. Its volume of distribution (Vd​) is approximately 55 liters, indicating distribution beyond the plasma into various tissues.[31] Valdecoxib is highly bound to plasma proteins, primarily albumin, with a binding fraction of approximately 98%.[1] This high degree of protein binding means that only a small fraction (~2%) of the drug is unbound or "free" to exert its pharmacological effect at any given time. This can also be a source of drug-drug interactions if other highly protein-bound drugs are co-administered. An interesting characteristic is that valdecoxib, but not the parent prodrug parecoxib, extensively partitions into erythrocytes (red blood cells).[31]

Biotransformation: Rapid Hydrolysis to Valdecoxib and Subsequent Hepatic Metabolism

The metabolism of parecoxib is a two-step process that defines its pharmacokinetic behavior:

1. Prodrug Conversion: The first and most rapid step is the hydrolysis of parecoxib. This reaction is catalyzed by carboxylesterase enzymes in the liver and almost completely converts parecoxib into its two constituent parts: the active drug, valdecoxib, and inactive propionic acid.[2] This conversion is so efficient that the plasma half-life of parecoxib itself is extremely short, measured at only about 22 minutes.[1]
2. Metabolite Metabolism: The subsequently formed valdecoxib is then eliminated via extensive hepatic metabolism involving multiple pathways.[31] The primary routes are oxidation reactions mediated by the cytochrome P450 (CYP) isoenzymes, mainly CYP3A4 and CYP2C9.[1] A secondary pathway involves glucuronidation (conjugation with glucuronic acid) of the sulfonamide moiety, which accounts for about 20% of its elimination.[31] The resulting metabolites are pharmacologically inactive and are more water-soluble, facilitating their excretion.[24]

Elimination Pathways and Half-Life

The inactive metabolites of valdecoxib are primarily eliminated by the kidneys. Approximately 70% of the administered dose is recovered in the urine as metabolites.[1] Very little of the active drug is excreted unchanged, with less than 5% of valdecoxib found in the urine.[31]

The biphasic nature of parecoxib's metabolism results in two distinct and clinically important half-lives. The short half-life of the prodrug ensures that the conversion to the active form is not a rate-limiting step, allowing for a rapid onset of action. The much longer half-life of the active metabolite provides the sustained analgesic effect necessary for convenient perioperative dosing. This elegant pharmacokinetic design achieves the dual goals of speed and duration, which are paramount in acute pain management.

Parameter	Parecoxib (Prodrug)	Valdecoxib (Active Metabolite)	Source(s)
Route of Administration	Intravenous, Intramuscular	Formed in vivo	1
Bioavailability	100%	N/A (formed from prodrug)	1
Time to Peak Concentration (Tmax​)	N/A	~30 min (IV), ~1 hr (IM)	31
Plasma Protein Binding	N/A	~98%	1
Volume of Distribution (Vd​)	N/A	~55 L	31
Primary Metabolism	Rapid enzymatic hydrolysis in liver	Hepatic oxidation (CYP3A4, CYP2C9) and glucuronidation	1
Elimination Half-life (t1/2​)	~22 minutes	~8 hours	1
Primary Excretion Route	N/A (converted to valdecoxib)	Renal (as inactive metabolites)	1
Table 2: Summary of Pharmacokinetic Parameters for Parecoxib and Valdecoxib

Clinical Efficacy in Postoperative Pain Management

The clinical utility of parecoxib is centered on its proven efficacy in managing acute postoperative pain. Its parenteral formulation and rapid onset of action make it particularly well-suited for the immediate perioperative period.

Approved Indications and Onset of Analgesic Action

Parecoxib is formally indicated for the short-term treatment of postoperative pain in adults.[4] Its use is specifically intended for patients who require parenteral therapy and for whom an oral analgesic would not provide a similar benefit, such as immediately after surgery when patients are unable to take medications by mouth.[11]

A key clinical feature is its rapid onset of analgesia. Following a single 40 mg IV or IM dose, the first perceptible pain relief occurs within 7 to 13 minutes.[1] Clinically meaningful pain relief is typically achieved within 23 to 39 minutes, with peak analgesic effects observed within two hours of administration.[1] This rapid action is crucial for managing the acute, severe pain that often follows surgical procedures.

Evidence from Clinical Trials

The efficacy of parecoxib has been robustly demonstrated across a wide range of surgical settings in numerous randomized controlled trials. These studies have consistently shown that parecoxib is significantly more effective than placebo for postoperative pain relief.[34] The primary surgical models in which its efficacy has been established include:

• Dental Surgery: Particularly in the post-oral surgery pain model following the extraction of impacted wisdom teeth.[34]
• Gynecological Surgery: Including post-hysterectomy pain.[23]
• Orthopedic Surgery: Such as total knee or hip arthroplasty and spinal fusion surgery.[34]
• General and Abdominal Surgery: Including laparoscopic procedures and major laparotomies.[37]

When compared to other active analgesics, parecoxib has demonstrated comparable efficacy to the potent non-selective NSAID ketorolac and has been shown to be superior to low-dose morphine in several postsurgical contexts.[5] The duration of analgesia from a single dose is typically between 6 and 12 hours, depending on the intensity of the pain and the specific surgical procedure, which aligns well with its pharmacokinetic profile.[34]

Role in Multimodal and Preemptive Analgesia Strategies

Beyond its use as a single agent, parecoxib's primary value in modern perioperative care lies in its role within a multimodal analgesia framework. This approach combines different classes of analgesics to achieve synergistic pain relief while minimizing the dose and side effects of each individual agent, particularly opioids.[9]

The clinical evidence demonstrates that parecoxib is not merely an alternative to opioids but a strategic tool that fundamentally improves the safety and efficacy of postoperative pain management. Opioids remain the cornerstone for severe pain but are associated with a significant burden of adverse effects—such as respiratory depression, sedation, nausea, vomiting, and ileus—that can impede recovery.[9] Parecoxib consistently produces a powerful

opioid-sparing effect. Clinical trials have shown that the addition of parecoxib to an opioid-based regimen can reduce total morphine consumption by 40-45% in the first 24 to 72 hours post-surgery.[35]

This reduction in opioid dosage translates directly into improved patient outcomes. By mitigating the need for high doses of opioids, parecoxib significantly lowers the incidence of opioid-related adverse events.[41] This, in turn, can lead to tangible benefits such as faster functional recovery, earlier mobilization, and shorter hospital stays.[38] Therefore, the clinical efficacy of parecoxib is best measured not just by its direct impact on pain scores, but by its enabling role in a broader strategy that makes postoperative recovery safer and faster.

Furthermore, the practice of preemptive analgesia, where an analgesic is administered before the surgical incision, has been shown to be effective with parecoxib. Preoperative administration can reduce the intensity of the initial postoperative pain and lower overall analgesic requirements, further contributing to enhanced recovery.[9]

Comprehensive Safety and Tolerability Profile

The safety profile of parecoxib is characterized by the advantages inherent to COX-2 selectivity, namely improved gastrointestinal and platelet safety, which are counterbalanced by the risks common to the coxib class, including potential cardiovascular and dermatological adverse events.

Overview of Common and Minor Adverse Events

In clinical trials, parecoxib is generally well-tolerated for short-term use. The most frequently reported adverse event is nausea.[5] Other common side effects, occurring in up to 1 in 10 patients, may include abdominal pain, vomiting, constipation, flatulence, dizziness, and hypokalemia (decreased potassium levels).[4] Events such as dyspepsia, transient changes in blood pressure, oliguria (decreased urine output), peripheral edema, and pruritus (itching) have also been reported more commonly with parecoxib than with placebo.[34]

In-Depth Analysis: Cardiovascular and Thromboembolic Risks

The most significant safety concern for the entire coxib class is the risk of cardiovascular (CV) and thromboembolic events. This risk became a major focus of regulatory scrutiny following the market withdrawal of rofecoxib (Vioxx) in 2004.[25]

• Class Effect and Mechanism: Long-term use of COX-2 inhibitors has been associated with an increased risk of myocardial infarction and stroke.[11] The prevailing hypothesis for this risk involves the disruption of the balance between two key prostanoids: thromboxane A2 (produced via COX-1 in platelets), which is pro-thrombotic, and prostacyclin (produced via COX-2 in the vascular endothelium), which is anti-thrombotic and vasodilatory. By selectively inhibiting COX-2, coxibs may shift this balance in favor of a pro-thrombotic state.[24]
• Coronary Artery Bypass Graft (CABG) Surgery: The risk appears to be most acute in specific high-risk settings. Two pivotal studies showed that patients receiving parecoxib for a minimum of 3 days followed by oral valdecoxib after CABG surgery had a significantly increased incidence of CV events compared to placebo.[1] This finding was critical and led to a firm contraindication against the use of parecoxib and all other NSAIDs for pain management immediately following CABG surgery.[4]
• Risk in Short-Term, Non-Cardiac Surgery: For its intended use—short-term (typically ≤3 days) management of pain in non-cardiac surgery—the risk appears to be substantially lower. A large pooled analysis of 28 clinical trials found that the incidence of CV embolic and thrombotic events was low (<1%) and comparable between parecoxib and placebo groups.[47] A 2017 analysis of post-marketing data covering over 69 million units of parecoxib also found that cardiac complications were minimal and not significantly different from placebo, suggesting the risk is most pronounced in specific high-risk populations or with longer-term use.[1]

In-Depth Analysis: Gastrointestinal Toxicity Profile

The primary rationale for developing selective COX-2 inhibitors was to improve gastrointestinal (GI) safety compared to non-selective NSAIDs, and parecoxib largely achieves this goal. By sparing the protective COX-1 enzyme in the gastric mucosa, parecoxib has a demonstrably lower risk of causing upper GI complications such as perforations, ulcers, and bleeds.[2] Clinical data confirm a low rate of GI-related adverse events, comparable to placebo.[23] However, the risk is not eliminated entirely, and caution is still warranted in patients with a history of GI disease. The risk of GI complications is elevated if parecoxib is used concomitantly with acetylsalicylic acid (aspirin), other NSAIDs, or alcohol.[46]

In-Depth Analysis: Dermatological Reactions and Sulfonamide Hypersensitivity

A distinct safety concern for parecoxib relates to its active metabolite, valdecoxib, which contains a sulfonamide chemical group.[11] This imparts a risk of hypersensitivity reactions, particularly severe skin reactions.

• Serious Skin Reactions: Post-marketing surveillance has identified rare but potentially fatal serious skin reactions, including Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome.[11] Notably, the reported rate of these severe events appeared to be greater for valdecoxib compared to other selective COX-2 inhibitors, a factor that contributed to its market withdrawal.[46]
• Sulfonamide Allergy: Patients with a known history of allergy to sulfonamide drugs ("sulfa" drugs) are at a greater risk of these skin reactions and should not receive parecoxib.[11] However, these reactions can also occur in patients without a history of sulfa allergy.[11]
• Hypersensitivity: Other hypersensitivity reactions, such as anaphylaxis and angioedema, have also been reported. It is imperative that parecoxib be discontinued immediately at the first appearance of any skin rash, mucosal lesions, or other signs of hypersensitivity.[11]

Renal and Hepatic Considerations

As with all NSAIDs, which can influence renal hemodynamics by inhibiting renal prostaglandins, caution is necessary when using parecoxib in patients with pre-existing conditions.

• Renal Impairment: Parecoxib should be used with caution in patients with renal impairment or those predisposed to fluid retention. For patients with severe renal impairment (creatinine clearance <30 mL/min), treatment should be initiated at the lowest recommended dose (20 mg) with close monitoring of kidney function.[4]
• Hepatic Impairment: The drug is contraindicated in patients with severe hepatic impairment (Child-Pugh Class C, score ≥10). In patients with moderate hepatic impairment (Child-Pugh Class B), the dose should be reduced.[4]

Contraindications, Warnings, and High-Risk Populations

The safe use of parecoxib is contingent on appropriate patient selection, which requires strict adherence to its contraindications and warnings. The pediatric population (under 18 years of age) is an off-label group, as safety and efficacy have not been established.[4]

Category	Specific Contraindications and Warnings	Source(s)
Absolute Contraindications	- Known hypersensitivity to parecoxib, valdecoxib, any NSAID, or sulfonamides. - History of serious allergic-type reactions (e.g., SJS, bronchospasm) to NSAIDs/aspirin. - Treatment of postoperative pain following Coronary Artery Bypass Graft (CABG) surgery. - Established ischemic heart disease, cerebrovascular disease, or peripheral arterial disease. - Active peptic ulceration or gastrointestinal bleeding. - Severe congestive heart failure (NYHA Class II-IV). - Severe hepatic impairment (Child-Pugh Class C). - Third trimester of pregnancy and breastfeeding.	4
Major Warnings & Precautions	- Cardiovascular Risk: Use with caution in patients with significant risk factors for CV events (e.g., hypertension, hyperlipidemia, diabetes, smoking). Use the lowest effective dose for the shortest possible duration. - Gastrointestinal Risk: Use with caution in elderly patients or those with a prior history of GI ulceration or bleeding. Avoid concomitant use with aspirin or other NSAIDs. - Skin Reactions: Discontinue immediately at the first sign of skin rash, mucosal lesions, or hypersensitivity. - Renal Impairment: Use with caution and at a reduced dose in patients with severe renal impairment. Monitor renal function. - Hepatic Impairment: Dose reduction is required for moderate hepatic impairment.	4
Table 3: Summary of Contraindications and Major Warnings for Parecoxib

Dosage, Administration, and Drug Interactions

Proper dosing, administration technique, and awareness of potential drug-drug interactions are critical for maximizing the efficacy and safety of parecoxib.

Recommended Dosing Regimens for Acute Pain

The dosing of parecoxib is standardized for the short-term management of acute postoperative pain in adults.

• Standard Adult Dose: The recommended initial dose is 40 mg, administered either intravenously (IV) or intramuscularly (IM). This may be followed by subsequent doses of 20 mg or 40 mg every 6 to 12 hours as needed for pain relief.[5]
• Maximum Daily Dose: The total daily dosage should not exceed 80 mg.[5]
• Duration of Treatment: Clinical experience with parecoxib is generally limited to three days of treatment, reflecting its indication for acute, short-term pain.[6]
• Special Populations: Dose adjustments are necessary for certain patient groups. In elderly patients who weigh less than 50 kg, the initial dose should be halved to 20 mg, and the maximum daily dose should be reduced to 40 mg.[6] Similar dose reductions are recommended for patients with moderate hepatic impairment.[6]

Guidelines for Intravenous and Intramuscular Administration

Parecoxib is supplied as a lyophilized powder that must be reconstituted prior to administration.

• Reconstitution: The powder should be reconstituted with a compatible sterile solution, such as 0.9% sodium chloride for injection. The final concentration after reconstitution is typically 20 mg/mL.[3]
• Incompatible Diluents: It is important to note that parecoxib is incompatible with certain IV solutions. For example, reconstitution with Lactated Ringer's Solution is not recommended, as it can cause the drug to precipitate out of solution.[3]
• Administration Technique: For IV administration, the reconstituted solution can be given as a bolus injection directly into a vein or into a compatible, existing IV line. For IM administration, the injection should be given slowly and deeply into a large muscle mass to ensure proper absorption and minimize local irritation.[33]

Clinically Significant Drug-Drug Interactions

As parecoxib's active metabolite, valdecoxib, undergoes extensive hepatic metabolism and is highly protein-bound, there is a significant potential for drug-drug interactions.

• Anticoagulants: Co-administration with oral anticoagulants, particularly warfarin, increases the risk of bleeding complications. Anticoagulant activity (e.g., INR) should be closely monitored, especially during the first few days after initiating parecoxib therapy.[6]
• CYP450 Interactions:
• Metabolism Inhibition: Valdecoxib is a substrate of CYP3A4 and CYP2C9. Concomitant use of strong inhibitors of these enzymes, such as the antifungal agents fluconazole (a CYP2C9 inhibitor) and ketoconazole (a CYP3A4 inhibitor), can significantly increase plasma concentrations of valdecoxib, potentially increasing the risk of adverse effects.[6]
• Metabolism Induction: Conversely, strong inducers of these enzymes (e.g., rifampicin, carbamazepine) could decrease valdecoxib concentrations, potentially reducing efficacy.[13]
• Inhibition of Other Enzymes: Valdecoxib itself is an inhibitor of CYP2D6 and CYP2C19. Therefore, it can increase the plasma concentrations of drugs metabolized by these enzymes, such as certain beta-blockers (metoprolol), antidepressants (imipramine), antipsychotics, and proton pump inhibitors (omeprazole).[6]
• Other NSAIDs and Aspirin: The concomitant use of parecoxib with other NSAIDs or even low-dose aspirin should be avoided, as this combination additively increases the risk of gastrointestinal ulceration and bleeding without providing additional analgesic benefit.[46]
• Antihypertensives: Parecoxib can attenuate the therapeutic effects of many antihypertensive drugs, including ACE inhibitors, angiotensin II receptor blockers (ARBs), beta-blockers, and diuretics. Blood pressure should be monitored when initiating parecoxib in patients on these medications.[6]
• Lithium: NSAIDs can reduce the renal clearance of lithium, leading to elevated plasma lithium levels and an increased risk of lithium toxicity. This interaction has been noted for parecoxib.[6]

Comparative Analysis with Alternative Analgesics

The clinical positioning of parecoxib is best understood through its comparison with other commonly used parenteral analgesics in the postoperative setting: non-selective NSAIDs (ketorolac), oral coxibs (celecoxib), and opioids.

Parecoxib vs. Non-Selective NSAIDs (Ketorolac)

Ketorolac is a potent, non-selective NSAID available for parenteral use and serves as a primary comparator for parecoxib.

• Efficacy: Head-to-head clinical trials have generally shown that the analgesic efficacy of parecoxib is comparable, and in some specific scenarios superior, to that of ketorolac.[37] For instance, a study in patients undergoing uvulopalatopharyngoplasty (UPPP) found that parecoxib provided significantly better pain relief for both resting and swallowing pain at 24 and 48 hours post-surgery compared to ketorolac.[39] In lumbar spinal fusion surgery, both drugs provided similar pain scores and were superior to placebo in the early postoperative period.[9]
• Safety and Clinical Niche: The most critical distinction lies in their safety profiles. As a non-selective NSAID, ketorolac inhibits both COX-1 and COX-2, which carries a significant risk of inhibiting platelet aggregation and increasing bleeding time, as well as a higher incidence of gastrointestinal toxicity.[8] In contrast, parecoxib's COX-2 selectivity means it has no clinically significant effect on platelet function and a much lower risk of GI complications.[8] This fundamental difference defines their clinical roles. Parecoxib is the superior and safer choice for patients undergoing surgeries with a high risk of bleeding, for those with pre-existing coagulopathies, or for patients with a history of peptic ulcer disease. In these scenarios, the higher acquisition cost of parecoxib is often justified by the significant reduction in the risk of serious complications.

Parecoxib vs. Oral COX-2 Inhibitors (Celecoxib)

Celecoxib is the most widely used oral selective COX-2 inhibitor.

• Efficacy: When comparing parenteral parecoxib to oral celecoxib, the route and speed of onset are key differentiators. A meta-analysis focused on orthopedic surgery concluded that IV parecoxib resulted in significantly greater pain reduction at 24, 48, and 72 hours post-op than oral celecoxib.[52] This is likely due to the more rapid and complete bioavailability achieved with parenteral administration.
• Clinical Niche: Parecoxib and celecoxib are not direct competitors but rather complementary agents in a continuum of care. Parecoxib is designed for the immediate postoperative period when patients are "nil by mouth" and require rapid-onset parenteral analgesia. Celecoxib is an excellent option for transitioning patients to an oral pain management regimen as they recover and are able to tolerate oral intake. This "IV-to-PO" sequential therapy (e.g., IV parecoxib followed by oral celecoxib) is a common and logical clinical strategy to maintain consistent COX-2 inhibition throughout the recovery process.[53]

Parecoxib vs. Opioids: Efficacy and Opioid-Sparing Benefits

Opioids are the mainstay for managing severe postoperative pain, but their utility is limited by a burdensome side-effect profile.

• Efficacy: For severe, acute pain, opioids generally provide more potent analgesia than parecoxib as a monotherapy. However, parecoxib is a powerful adjunct. When added to a patient-controlled analgesia (PCA) regimen with opioids, parecoxib significantly improves overall pain control compared to PCA with opioids alone.[23]
• Safety and Opioid-Sparing Benefits: The primary advantage of parecoxib in this context is its role as a cornerstone of an opioid-sparing strategy. It lacks the hallmark adverse effects of opioids, such as respiratory depression, excessive sedation, nausea, and pruritus.[40] As previously noted, clinical trials consistently show that incorporating parecoxib into the analgesic plan significantly reduces the total cumulative dose of opioids required by 40-45%.[38] This dose reduction leads to a corresponding and clinically meaningful decrease in the incidence and severity of opioid-related side effects, facilitating a smoother and faster recovery.[23]

Feature	Parecoxib	Ketorolac (Non-selective NSAID)	Celecoxib (Oral Coxib)	Opioids (e.g., Morphine)
Analgesic Efficacy	High; comparable or superior to ketorolac	High; comparable to parecoxib	Moderate to High	Very High (for severe pain)
Route / Onset	IV/IM; Rapid (7-13 min)	IV/IM; Rapid	Oral; Slower (30-60 min)	IV/IM/Oral; Rapid (IV)
GI Risk	Low	High	Low	Low (but causes constipation)
Bleeding Risk (Platelet Effect)	None	High (inhibits platelet aggregation)	None	None
Cardiovascular Risk	Class risk (contraindicated in IHD/CVA/CABG)	Moderate risk; less than coxibs in some contexts	Class risk (contraindicated in IHD/CVA/CABG)	Low
Common Side Effects	Nausea, headache, dizziness	GI distress, renal impairment, bleeding	Headache, dyspepsia	Nausea, vomiting, sedation, respiratory depression, pruritus, constipation
Clinical Niche	Parenteral analgesia in patients with GI/bleeding risks; cornerstone of opioid-sparing multimodal analgesia.	Parenteral analgesia in low-risk patients; cost-effective alternative.	Oral transition from parenteral NSAIDs; management of subacute pain.	Management of moderate-to-severe pain; primary agent in PCA.
Table 4: Head-to-Head Efficacy and Safety Comparison Summary

Global Regulatory Landscape: A Tale of Two Agencies

The regulatory history of parecoxib is a compelling case study in how scientific data, clinical context, and external pressures can lead to dramatically different outcomes in major global markets. While widely accepted in Europe and other regions, it remains unapproved in the United States.

Authorization and Post-Marketing Surveillance in the European Union (EMA)

Parecoxib, marketed as Dynastat, received a centralized marketing authorization valid throughout the European Union from the European Medicines Agency (EMA) on March 22, 2002.[1] The approved indication is for the short-term treatment of postoperative pain.[5] The EMA's Committee for Medicinal Products for Human Use (CHMP) concluded that, for this specific indication, the benefits of parecoxib in providing effective parenteral pain relief outweighed its known risks.[5] The agency deemed the side effects to be manageable through appropriate patient selection, contraindications, and warnings, which are clearly outlined in the product's Summary of Product Characteristics (SmPC).[5] As with all authorized medicines, parecoxib is subject to continuous post-marketing surveillance and pharmacovigilance activities to monitor its safety in real-world clinical practice.[5]

The U.S. FDA Non-Approval: A Critical Analysis

In stark contrast to the EMA's decision, the United States Food and Drug Administration (FDA) issued a "non-approvable" letter for parecoxib in September 2005.[1] The FDA has never publicly documented the specific scientific reasons for this rejection, a lack of transparency that has fueled considerable debate.[1] However, an analysis of the scientific and regulatory climate of the time provides a clear context for the decision.

The review of parecoxib's New Drug Application (NDA) occurred in the immediate aftermath of the 2004 voluntary withdrawal of rofecoxib (Vioxx), another selective COX-2 inhibitor, due to unequivocal evidence of increased cardiovascular risk with long-term use.[25] This event created a crisis of public and political confidence and placed immense pressure on the FDA to adopt an extremely conservative stance toward any new drug in the coxib class.[1]

The scientific concerns likely centered on two main areas: the increased risk of cardiovascular events observed in post-CABG surgery trials and the rare but serious skin reactions associated with valdecoxib (Bextra), which itself was withdrawn from the market in 2005.[1] However, it is noteworthy that the post-CABG risk was already being addressed with a class-wide contraindication, and other NSAIDs with known risks remained on the market with appropriate warnings.[1] The decision to reject parecoxib outright, rather than approve it with stringent restrictions and warnings as the EMA had done, suggests that the regulatory bar for this specific drug class had been raised to a level that was politically, and perhaps practically, insurmountable at the time.

Subsequent evidence, including a large 2017 pooled analysis showing minimal difference in cardiac and skin complications between parecoxib and placebo in its intended use, lends further support to the hypothesis that the FDA's decision was a product of a unique, post-Vioxx regulatory environment rather than a reflection of an unacceptable risk-benefit profile for the short-term, parenteral use of parecoxib.[1] Parecoxib can thus be seen as a casualty of its time, its approval hindered by the "class effect" shadow cast by its predecessors.

Legal and Regulatory Status in Other Key Regions

Reflecting the EMA's assessment, parecoxib has been approved for use in many other countries. Its legal status includes:

• Australia (AU): Schedule 4 (S4), Prescription Only Medicine.[1]
• United Kingdom (UK): Prescription Only Medicine (POM).[1]
• Brazil (BR): Class C1 (Other controlled substances).[1]

Synthesis and Expert Recommendations

Integrated Assessment of the Risk-Benefit Profile

Parecoxib presents a complex but ultimately favorable risk-benefit profile when used appropriately within its specified indication. Its benefits are clear and significant: it is a potent, rapid-acting parenteral analgesic that provides an effective non-opioid option for the management of acute postoperative pain. Its selective COX-2 inhibition mechanism confers a distinct safety advantage over non-selective NSAIDs regarding gastrointestinal toxicity and platelet dysfunction, which are critical considerations in the surgical patient population. Furthermore, its robust opioid-sparing effect is a cornerstone of modern multimodal analgesia, contributing to reduced opioid-related adverse events and facilitating enhanced recovery after surgery.

These benefits must be weighed against its established risks. The cardiovascular risk, while a characteristic of the coxib class, appears to be most pronounced in the specific high-risk setting of post-CABG surgery, which is now a firm contraindication. For short-term use in non-cardiac surgery patients without pre-existing cardiovascular disease, the absolute risk appears low and comparable to placebo. The risk of rare but serious skin reactions is a significant concern that necessitates careful patient screening, particularly for sulfonamide allergies, and immediate discontinuation at the first sign of a reaction.

In summary, for the indicated population—adults requiring short-term parenteral analgesia post-operatively who do not have contraindications related to cardiovascular disease, GI bleeding, or sulfonamide allergy—the evidence supports a positive benefit-risk balance. This conclusion is underscored by its successful and widespread use for two decades in regions regulated by the EMA and other health authorities.

Recommendations for Optimal Clinical Application

Based on a comprehensive review of the evidence, the optimal clinical application of parecoxib can be defined by strategic patient selection:

1. Primary Indication: Parecoxib should be considered a first-line parenteral NSAID for postoperative pain management in adult patients undergoing major non-cardiac surgery, particularly when oral administration is not feasible.
2. Patient Stratification: It is the preferred parenteral NSAID over non-selective agents like ketorolac in patients with an elevated risk of gastrointestinal complications (e.g., history of peptic ulcer disease) or bleeding (e.g., surgeries with high bleeding potential, patients with coagulopathy).
3. Multimodal Analgesia: Its primary role is as a foundational component of an opioid-sparing multimodal analgesic regimen. It should be administered on a scheduled basis (e.g., every 12 hours) to provide a baseline of non-opioid analgesia, thereby reducing the total dose of opioids required for breakthrough pain.
4. Contraindication Adherence: Strict adherence to contraindications is paramount. It should not be used in patients with established ischemic heart disease, cerebrovascular disease, post-CABG surgery, severe heart failure, or a history of sulfonamide allergy.

Identified Gaps and Directions for Future Research

Despite two decades of clinical use, several areas warrant further investigation:

• Non-COX-Mediated Mechanisms: The discovery of parecoxib's direct inhibitory effects on neuronal ion channels is a significant finding. Future research should aim to elucidate the clinical relevance of this secondary mechanism. Studies could investigate whether this property contributes to a superior analgesic effect in specific pain states (e.g., neuropathic pain components) compared to other coxibs that may lack this action.
• Pharmacoeconomics: While parecoxib is more expensive than older parenteral analgesics like ketorolac, its improved safety profile may lead to overall cost savings by preventing costly complications (e.g., GI bleeds). More robust, region-specific pharmacoeconomic analyses are needed to quantify this value proposition and guide formulary decisions in various healthcare systems.
• Dermatological Risk Quantification: The observation that the rate of serious skin reactions may be higher for valdecoxib than for other coxibs requires further clarification. Large-scale epidemiological studies could help to more precisely quantify this risk and identify any specific predisposing factors beyond sulfonamide allergy.

Works cited

1. Parecoxib - Wikipedia, accessed August 19, 2025, https://en.wikipedia.org/wiki/Parecoxib
2. What is the mechanism of Parecoxib Sodium? - Patsnap Synapse, accessed August 19, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-parecoxib-sodium
3. Dynastat, INN - parecoxib, accessed August 19, 2025, https://www.ema.europa.eu/en/documents/scientific-discussion/dynastat-epar-scientific-discussion_en.pdf
4. Parecoxib - Uses, Dosage, Side Effects, Price, Composition | Practo, accessed August 19, 2025, https://www.practo.com/medicine-info/parecoxib-1360-api
5. Dynastat | European Medicines Agency (EMA), accessed August 19, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/dynastat
6. Parecoxib - EMed, accessed August 19, 2025, https://emed.ie/Pharmacology/Parecoxib.php
7. Discovery and development of cyclooxygenase 2 inhibitors - Wikipedia, accessed August 19, 2025, https://en.wikipedia.org/wiki/Discovery_and_development_of_cyclooxygenase_2_inhibitors
8. Parecoxib sodium | Dynastat | SC-69124A | CAS#198470-85-8 - MedKoo Biosciences, accessed August 19, 2025, https://www.medkoo.com/products/10858
9. Comparing parecoxib and ketorolac as preemptive analgesia in patients undergoing posterior lumbar spinal fusion: a prospective randomized double-blinded placebo-controlled trial - PMC - PubMed Central, accessed August 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4369094/
10. Selective inhibitors of cyclooxygenase-2 (COX-2), celecoxib and parecoxib: a systematic review - ResearchGate, accessed August 19, 2025, https://www.researchgate.net/publication/51442627_Selective_inhibitors_of_cyclooxygenase-2_COX-2_celecoxib_and_parecoxib_a_systematic_review
11. PARECOXIB - Pfizer, accessed August 19, 2025, https://labeling.pfizer.com/ShowLabeling.aspx?id=12872
12. Parecoxib: What is it and is it FDA approved? - Drugs.com, accessed August 19, 2025, https://www.drugs.com/history/parecoxib.html
13. Parecoxib: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 19, 2025, https://go.drugbank.com/drugs/DB08439
14. parecoxib | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY, accessed August 19, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2895
15. Parecoxib 198470-84-7 | Tokyo Chemical Industry Co., Ltd.(APAC), accessed August 19, 2025, https://www.tcichemicals.com/OP/en/p/P2579
16. Parecoxib | 198470-84-7 - ChemicalBook, accessed August 19, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB81515695.htm
17. Parecoxib Sodium | C19H17N2NaO4S | CID 15895902 - PubChem, accessed August 19, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/15895902
18. MATERIAL SAFETY DATA SHEET - Pfizer, accessed August 19, 2025, https://cdn.pfizer.com/pfizercom/products/material_safety_data/PZ01054.pdf
19. Parecoxib Unknown Status Phase N/A Trials for Postoperative pain Treatment - DrugBank, accessed August 19, 2025, https://go.drugbank.com/drugs/DB08439/clinical_trials?conditions=DBCOND0022333&purpose=treatment&status=unknown_status
20. CAS 198470-84-7 - Sigma-Aldrich, accessed August 19, 2025, https://www.sigmaaldrich.com/US/en/search/198470-84-7?focus=products&page=1&perpage=30&sort=relevance&term=198470-84-7&type=cas_number
21. Parecoxib sodium | DrugBank Online, accessed August 19, 2025, https://go.drugbank.com/salts/DBSALT002342
22. Parecoxib Sodium-SDS-MedChemExpress, accessed August 19, 2025, https://file.medchemexpress.com/batch_PDF/HY-17474A/Parecoxib-Sodium-SDS-MedChemExpress.pdf
23. Efficacy and safety of parecoxib sodium for acute postoperative pain: A meta-analysis - PMC, accessed August 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3786997/
24. Pharmacology of non-steroidal anti-inflammatory agents | Deranged Physiology, accessed August 19, 2025, https://derangedphysiology.com/main/cicm-primary-exam/nervous-system/Chapter-334/pharmacology-non-steroidal-anti-inflammatory-agents
25. COX-2 Inhibitors: What They Are, Uses & Side Effects, accessed August 19, 2025, https://my.clevelandclinic.org/health/drugs/23119-cox-2-inhibitors
26. NSAIDs between past and present; a long journey towards an ideal COX-2 inhibitor lead, accessed August 19, 2025, https://pubs.rsc.org/en/content/articlehtml/2024/ra/d4ra04686b
27. Selective COX-2 Inhibitors: Road from Success to Controversy and the Quest for Repurposing, accessed August 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9318302/
28. COX-2 Selectivity of NSAIDs: Molecular Docking Analysis with AutoDock & Vina - Bionatura journal, accessed August 19, 2025, https://bionaturajournal.com/2025.02.02.3.html
29. Valdecoxib: Assessment of Cyclooxygenase-2 Potency and Selectivity - ResearchGate, accessed August 19, 2025, https://www.researchgate.net/publication/8221669_Valdecoxib_Assessment_of_Cyclooxygenase-2_Potency_and_Selectivity
30. Parecoxib, a selective blocker of cyclooxygenase-2, directly inhibits ..., accessed August 19, 2025, https://pubmed.ncbi.nlm.nih.gov/30529469/
31. Dynastat 40mg Powder for Solution for Injection - Summary of Product Characteristics (SmPC) - (emc) | 1606, accessed August 19, 2025, https://www.medicines.org.uk/emc/product/1606/smpc
32. Simultaneous Determination of Parecoxib and Its Metabolite Valdecoxib Concentrations in Beagle Plasma by UPLC-MS/MS and Application for Pharmacokinetics Study - PMC - PubMed Central, accessed August 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7078782/
33. DYNASTAT® - Pfizer, accessed August 19, 2025, https://labeling.pfizer.com/ShowLabeling.aspx?id=12244
34. Parecoxib - Australian Prescriber - Therapeutic Guidelines, accessed August 19, 2025, https://australianprescriber.tg.org.au/articles/parecoxib.html
35. A randomized study of the efficacy and safety of parecoxib for the treatment of pain following total knee arthroplasty in Korean patients, accessed August 19, 2025, https://www.dovepress.com/a-randomized-study-of-the-efficacy-and-safety-of-parecoxib-for-the-tre-peer-reviewed-fulltext-article-JPR
36. Parecoxib (parecoxib sodium) - PubMed, accessed August 19, 2025, https://pubmed.ncbi.nlm.nih.gov/11465874/
37. Emerging Drug List - PARECOXIB SODIUM, accessed August 19, 2025, https://www.cda-amc.ca/sites/default/files/pdf/108_No10_parecoxib_edrug_e.pdf
38. Preoperative Administration of Parecoxib for Postoperative Pain Management in Cervical Laminoplasty: A Retrospective Study - World Journal of Surgery and Surgical Research, accessed August 19, 2025, https://www.surgeryresearchjournal.com/open-access/preoperative-administration-of-parecoxib-for-postoperative-pain-management-in-cervical-8564.pdf
39. Comparative Analysis of Ketorolac and Parecoxib for Postoperative ..., accessed August 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11312481/
40. Comparative Analysis of Ketorolac and Parecoxib for Postoperative Pain Management in Uvulopalatopharyngoplasty - MDPI, accessed August 19, 2025, https://www.mdpi.com/2077-0383/13/15/4422
41. Parecoxib relieves pain and has an opioid-sparing effect following major gastrointestinal surgery - Dove Medical Press, accessed August 19, 2025, https://www.dovepress.com/parecoxib-relieves-pain-and-has-an-opioid-sparing-effect-following-maj-peer-reviewed-fulltext-article-IJGM
42. Cyclooxygenase-2–selective inhibitors in the management of acute and perioperative pain, accessed August 19, 2025, https://www.ccjm.org/content/ccjom/69/4_suppl_1/SI-65.full.pdf
43. Parecoxib Reduced Postsurgical Pain and Facilitated Movement More Than Patient Controlled Analgesia - Frontiers, accessed August 19, 2025, https://www.frontiersin.org/journals/surgery/articles/10.3389/fsurg.2022.799795/full
44. A cost-consequence analysis of parecoxib and opioids vs opioids alone for postoperative pain: Chinese perspective - Dove Medical Press, accessed August 19, 2025, https://www.dovepress.com/a-cost-consequence-analysis-of-parecoxib-and-opioids-vs-opioids-alone--peer-reviewed-fulltext-article-CEOR
45. pubmed.ncbi.nlm.nih.gov, accessed August 19, 2025, https://pubmed.ncbi.nlm.nih.gov/11465874/#:~:text=Nausea%2C%20abdominal%20pain%2C%20headache%2C,parecoxib%20recipients%20after%20gynaecological%20surgery.
46. Dynastat, INN-parecoxib - European Medicines Agency, accessed August 19, 2025, https://www.ema.europa.eu/en/documents/product-information/dynastat-epar-product-information_en.pdf
47. The safety profile of parecoxib for the treatment of postoperative pain ..., accessed August 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5644539/
48. Parecoxib-AFT 40 mg powder for injection. - Medsafe, accessed August 19, 2025, https://www.medsafe.govt.nz/Profs/Datasheet/p/ParecoxibAFTinj.pdf
49. Comparison of postoperative analgesic efficacy and safety of parecoxib and ketorolac in patients of inguinal hernia | International Journal of Basic & Clinical Pharmacology, accessed August 19, 2025, https://www.ijbcp.com/index.php/ijbcp/article/view/1292
50. (PDF) Comparing parecoxib and ketorolac as preemptive analgesia in patients undergoing posterior lumbar spinal fusion: A prospective randomized double-blinded placebo-controlled trial - ResearchGate, accessed August 19, 2025, https://www.researchgate.net/publication/276884177_Comparing_parecoxib_and_ketorolac_as_preemptive_analgesia_in_patients_undergoing_posterior_lumbar_spinal_fusion_A_prospective_randomized_double-blinded_placebo-controlled_trial
51. Efficacy and safety of perioperative parecoxib for acute ..., accessed August 19, 2025, https://journal.hep.com.cn/fmd/EN/10.1007/s11684-015-0414-y
52. Efficacy and characteristics of parecoxib and celecoxib in the ..., accessed August 19, 2025, https://www.cjter.com/EN/10.3969/j.issn.2095-4344.2489
53. Pain Completed Phase 4 Trials for Parecoxib (DB08439) | DrugBank Online, accessed August 19, 2025, https://go.drugbank.com/indications/DBCOND0012160/clinical_trials/DB08439?phase=4&status=completed
54. Efficacy and safety of Postoperative Intravenous Parecoxib sodium Followed by ORal CElecoxib (PIPFORCE) post-total knee arthroplasty in patients with osteoarthritis: a study protocol for a multicentre, double-blind, parallel-group trial - PMC - PubMed Central, accessed August 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5020851/
55. Efficacy and safety of parecoxib sodium for acute postoperative pain: A meta-analysis, accessed August 19, 2025, https://www.spandidos-publications.com/10.3892/etm.2013.1172
56. Parecoxib versus Tramadol for Post-Appendectomy Pain, accessed August 19, 2025, http://www.jmatonline.com/PDF/88-PB-1557-1562.pdf
57. parecoxib | Ligand page | IUPHAR/BPS Guide to IMMUNOPHARMACOLOGY, accessed August 19, 2025, https://www.guidetoimmunopharmacology.org/GRAC/LigandDisplayForward?tab=clinical&ligandId=2895